title: New drugs08, part 2.
abstract: In this article, you'll learn about eight new drugs, including: doripenem, an antibiotic for complicated intra-abdominal and urinary tract infections. Maraviroc, a new antiretroviral agent to treat HIV infection. Ixabepilone, a new drug for refractory metastatic breast cancer. Unless otherwise specified, the information in the following summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breast-feeding. Also consult a pharmacist, the package insert, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions for all these drugs.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
mesh_terms: D000172:Acromegaly / Q000188:drug therapy; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001708:Biopterins / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015780:Carbapenems / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D000077726:Doripenem; D004358:Drug Therapy / Q000451:nursing*; D064420:Drug-Related Side Effects and Adverse Reactions; D034261:Epothilones / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D000077592:Maraviroc; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010661:Phenylketonurias / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D015780:Carbapenems; D003510:Cyclohexanes; D034261:Epothilones; D010456:Peptides, Cyclic; D004364:Pharmaceutical Preparations; D011743:Pyrimidines; D011760:Pyrrolidinones; D014230:Triazoles; C060347:lanreotide; D001708:Biopterins; D000068898:Raltegravir Potassium; D013004:Somatostatin; C401859:temsirolimus; D000077726:Doripenem; C003402:sapropterin; C498826:nilotinib; C430592:ixabepilone; D000077592:Maraviroc; D020123:Sirolimus